
News|Articles|December 1, 2006
FDA Actions in Brief (December 2006)
Imatinib (Gleevec, Novartis) was approved for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Whole Health and Pharmacy: The Overlooked Alliance in Chronic Disease Management
2
Almost Half of Severe Alopecia Areata Pediatric Patients Saw Hair Regrowth on Olumiant, Study Shows | 2025 Fall Clinical Derm
3
Beyond Sotyktu: Next-Gen TYK2 Drugs Enter Late-Stage Development | Fall Clinical Derm 2025
4
Discussing Innovative Research in Vitiligo
5

















































